{"id":1011961,"date":"2026-10-20T16:22:48","date_gmt":"2026-10-20T20:22:48","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/inhibikase-therapeutics-appoints-scott-wasserman-to-board-of-directors\/"},"modified":"2026-10-20T16:22:48","modified_gmt":"2026-10-20T20:22:48","slug":"inhibikase-therapeutics-appoints-scott-wasserman-to-board-of-directors","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/inhibikase-therapeutics-appoints-scott-wasserman-to-board-of-directors\/","title":{"rendered":"Inhibikase Therapeutics Appoints Scott Wasserman to Board of Directors"},"content":{"rendered":"
\n

WILMINGTON, Del., Oct. 20, 2026 (GLOBE NEWSWIRE) — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (\u201cInhibikase\u201d or \u201cCompany\u201d), a clinical-stage pharmaceutical company developing IKT-001, a novel once-daily oral anti-proliferative for Pulmonary Arterial Hypertension (\u201cPAH\u201d), today announced the appointment of Scott M. Wasserman, MD, to the Company\u2019s Board of Directors, effective October 19, 2026. Concurrent with Dr. Wasserman\u2019s appointment, the Company also announced the resignation of Dennis Berman from the Company\u2019s Board.<\/p>\n

\u201cWe thank Dennis for his many contributions to the Company during his years of service,\u201d said Amit Munshi, Chair of the Inhibikase Board of Directors.<\/p>\n

Dr. Wasserman is currently the Chief Medical Officer of Kailera Therapeutics, a clinical-stage company developing GLP-1-based therapeutics for obesity and related conditions. Dr. Wasserman is a cardiologist with more than two decades of experience in clinical development and company leadership. At Amgen Inc., he served as Vice President, Global Development and Therapeutic Area Head for Bone, Cardiovascular, Metabolic and Neuroscience. He was Amgen\u2019s first cardiologist and built the company\u2019s cardiovascular and metabolic strategy, team and portfolio. He led the global development and approvals of Repatha (evolocumab), was instrumental in the development and U.S. FDA approval of Evenity (romosozumab) and oversaw the U.S. approval of Aimovig (erenumab).<\/p>\n

\u201cScott has taken multiple programs from early development through global approval, and he has built clinical organizations at both large and emerging companies,\u201d said Amit Munshi. \u201cWe look forward to benefiting from his expertise as we continue to advance our global Phase 3 IMPROVE-PAH study of IKT-001. We are pleased to welcome Scott to our Board.<\/p>\n

\u201cPAH is a progressive, life-threatening disease, and the pedigree of imatinib together with the recent preclinical and Phase 1 data for IKT-001 point to a very promising role for this asset in this difficult to treat condition,\u201d said Dr. Wasserman. \u201cThis is an important time for Inhibikase, and I look forward to applying my experience in global clinical development and regulatory interactions as the Company advances IMPROVE-PAH.\u201d<\/p>\n

Scott brings deep expertise in clinical development to Inhibikase\u2019s Board of Directors, spanning global development strategy, clinical trial design and execution, and global regulatory interactions. Most recently, Scott served as Venture Partner at Frazier Life Sciences, focusing on company creation. Prior to Frazier, Scott was the CEO and co-founder of Latigo Biotherapeutics, a venture-backed biotechnology company developing first and best-in-class, non-opioid pain medicines. Prior to his role with Latigo, Scott was Vice President, Global Development Therapeutic Area Head for Bone, Cardiovascular, Metabolic, and Neuroscience at Amgen. In addition to his role in the development of Repatha, Evenity, and Aimovig, Scott oversaw therapeutic development for a range of other conditions, including heart failure, anemia, obesity, and Alzheimer\u2019s disease.<\/p>\n

Prior to joining industry, Scott was on faculty at Stanford University in the Division of Cardiovascular Medicine conducting NIH-sponsored research on endothelial gene expression and served as a non-interventional cardiologist at the Veterans Administration Hospital in Palo Alto, CA. Scott received his BS, Magna Cum Laude from Haverford College and his MD, Magna Cum Laude from Harvard Medical School. He completed his postgraduate training in Internal Medicine and Cardiovascular Medicine at Stanford University and post-doctoral cardiovascular research at COR Therapeutics, Millennium Pharmaceuticals, and Stanford.<\/p>\n

\n About Inhibikase (www.inhibikase.com<\/a>)\u00a0<\/strong>\n <\/p>\n

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) is a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (\u201cPAH\u201d), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as \u201cc-Kit,\u201d has been implicated. Our lead product candidate\u00a0is IKT-001, a prodrug of imatinib mesylate (\u201cimatinib\u201d), for PAH which is an orphan indication. Imatinib was first approved in the United States in 2001 for various cancers and blood disorders and, following more than 20 years of clinical use, has a well-characterized safety profile with the first reported use of imatinib in PAH occurring in 2005. PAH is a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance that affects approximately 50,000 Americans.\u00a0Our single pivotal Phase 3 clinical study in PAH in approximately 180 sites around the world, named IMPROVE-PAH (I<\/strong>KT-001 for M<\/strong>easuring P<\/strong>ulmonary Vascular R<\/strong>esistance and O<\/strong>utcome V<\/strong>ariables in a Phase 3 E<\/strong>valuation of PAH<\/strong>), is actively enrolling patients.<\/p>\n

\n Social Media Disclaimer<\/strong>\n <\/p>\n

Investors and others should note that the Company announces material financial information to investors using its investor relations website, press releases, SEC filings and public conference calls and webcasts. The Company intends to also use LinkedIn\u00a0as a means of disclosing information about the Company, its services and other matters and for complying with its disclosure obligations under Regulation FD.<\/p>\n

\n Forward-Looking Statements<\/strong>\n <\/p>\n

This press release contains \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking terminology such as \u201cbelieves,\u201d \u201cexpects,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201canticipates,\u201d \u201cplans,\u201d or similar expressions or the negative of these terms and similar expressions are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the potential of IKT-001, the advancement of the IMPROVE-PAH study, and the anticipated contribution of Dr. Wasserman to the Company’s board of directors. These forward-looking statements are based on Inhibikase\u2019s current expectations and assumptions. Such statements are subject to certain risks and uncertainties, which could cause Inhibikase\u2019s actual results to differ materially from those anticipated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include our ability to execute a Phase 3 study to evaluate IKT-001 as a treatment for PAH, as well as such other factors that are included in our periodic reports on Form 10-K and Form 10-Q that we file with the U.S. Securities and Exchange Commission. Any forward-looking statement in this release speaks only as of the date of this release. Inhibikase undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.<\/p>\n

\n Contacts:<\/strong>
\n
\n Investor Relations:<\/em>
\n
Michael Moyer
LifeSci Advisors
mmoyer@lifesciadvisors.com<\/a>\u00a0<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

WILMINGTON, Del., Oct. 20, 2026 (GLOBE NEWSWIRE) — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (\u201cInhibikase\u201d or \u201cCompany\u201d), a clinical-stage pharmaceutical company developing IKT-001, a novel once-daily oral anti-proliferative for Pulmonary Arterial Hypertension (\u201cPAH\u201d), today announced the appointment of Scott M. Wasserman, MD, to the Company\u2019s Board of Directors, effective October 19, 2026. Concurrent with Dr. Wasserman\u2019s appointment, the Company also announced the resignation of Dennis Berman from the Company\u2019s Board. \u201cWe thank Dennis for his many contributions to the Company during his years of service,\u201d said Amit Munshi, Chair of the Inhibikase Board of Directors. Dr. Wasserman is currently the Chief Medical Officer of Kailera Therapeutics, a clinical-stage company developing GLP-1-based therapeutics for obesity and related conditions. Dr. Wasserman is a … <\/p>\n

Continue reading “Inhibikase Therapeutics Appoints Scott Wasserman to Board of Directors”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1011961","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nInhibikase Therapeutics Appoints Scott Wasserman to Board of Directors - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/inhibikase-therapeutics-appoints-scott-wasserman-to-board-of-directors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Inhibikase Therapeutics Appoints Scott Wasserman to Board of Directors - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WILMINGTON, Del., Oct. 20, 2026 (GLOBE NEWSWIRE) — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (\u201cInhibikase\u201d or \u201cCompany\u201d), a clinical-stage pharmaceutical company developing IKT-001, a novel once-daily oral anti-proliferative for Pulmonary Arterial Hypertension (\u201cPAH\u201d), today announced the appointment of Scott M. Wasserman, MD, to the Company\u2019s Board of Directors, effective October 19, 2026. Concurrent with Dr. Wasserman\u2019s appointment, the Company also announced the resignation of Dennis Berman from the Company\u2019s Board. \u201cWe thank Dennis for his many contributions to the Company during his years of service,\u201d said Amit Munshi, Chair of the Inhibikase Board of Directors. Dr. Wasserman is currently the Chief Medical Officer of Kailera Therapeutics, a clinical-stage company developing GLP-1-based therapeutics for obesity and related conditions. Dr. Wasserman is a … Continue reading "Inhibikase Therapeutics Appoints Scott Wasserman to Board of Directors"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/inhibikase-therapeutics-appoints-scott-wasserman-to-board-of-directors\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-20T20:22:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0OTc5NiM3OTA2ODk5IzIxNTY3NjI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inhibikase-therapeutics-appoints-scott-wasserman-to-board-of-directors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inhibikase-therapeutics-appoints-scott-wasserman-to-board-of-directors\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Inhibikase Therapeutics Appoints Scott Wasserman to Board of Directors\",\"datePublished\":\"2026-10-20T20:22:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inhibikase-therapeutics-appoints-scott-wasserman-to-board-of-directors\\\/\"},\"wordCount\":1010,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inhibikase-therapeutics-appoints-scott-wasserman-to-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0OTc5NiM3OTA2ODk5IzIxNTY3NjI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inhibikase-therapeutics-appoints-scott-wasserman-to-board-of-directors\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inhibikase-therapeutics-appoints-scott-wasserman-to-board-of-directors\\\/\",\"name\":\"Inhibikase Therapeutics Appoints Scott Wasserman to Board of Directors - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inhibikase-therapeutics-appoints-scott-wasserman-to-board-of-directors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inhibikase-therapeutics-appoints-scott-wasserman-to-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0OTc5NiM3OTA2ODk5IzIxNTY3NjI=\",\"datePublished\":\"2026-10-20T20:22:48+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inhibikase-therapeutics-appoints-scott-wasserman-to-board-of-directors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inhibikase-therapeutics-appoints-scott-wasserman-to-board-of-directors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inhibikase-therapeutics-appoints-scott-wasserman-to-board-of-directors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0OTc5NiM3OTA2ODk5IzIxNTY3NjI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0OTc5NiM3OTA2ODk5IzIxNTY3NjI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inhibikase-therapeutics-appoints-scott-wasserman-to-board-of-directors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Inhibikase Therapeutics Appoints Scott Wasserman to Board of Directors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Inhibikase Therapeutics Appoints Scott Wasserman to Board of Directors - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/inhibikase-therapeutics-appoints-scott-wasserman-to-board-of-directors\/","og_locale":"en_US","og_type":"article","og_title":"Inhibikase Therapeutics Appoints Scott Wasserman to Board of Directors - Market Newsdesk","og_description":"WILMINGTON, Del., Oct. 20, 2026 (GLOBE NEWSWIRE) — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (\u201cInhibikase\u201d or \u201cCompany\u201d), a clinical-stage pharmaceutical company developing IKT-001, a novel once-daily oral anti-proliferative for Pulmonary Arterial Hypertension (\u201cPAH\u201d), today announced the appointment of Scott M. Wasserman, MD, to the Company\u2019s Board of Directors, effective October 19, 2026. Concurrent with Dr. Wasserman\u2019s appointment, the Company also announced the resignation of Dennis Berman from the Company\u2019s Board. \u201cWe thank Dennis for his many contributions to the Company during his years of service,\u201d said Amit Munshi, Chair of the Inhibikase Board of Directors. Dr. Wasserman is currently the Chief Medical Officer of Kailera Therapeutics, a clinical-stage company developing GLP-1-based therapeutics for obesity and related conditions. Dr. Wasserman is a … Continue reading \"Inhibikase Therapeutics Appoints Scott Wasserman to Board of Directors\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/inhibikase-therapeutics-appoints-scott-wasserman-to-board-of-directors\/","og_site_name":"Market Newsdesk","article_published_time":"2026-10-20T20:22:48+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0OTc5NiM3OTA2ODk5IzIxNTY3NjI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inhibikase-therapeutics-appoints-scott-wasserman-to-board-of-directors\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inhibikase-therapeutics-appoints-scott-wasserman-to-board-of-directors\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Inhibikase Therapeutics Appoints Scott Wasserman to Board of Directors","datePublished":"2026-10-20T20:22:48+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inhibikase-therapeutics-appoints-scott-wasserman-to-board-of-directors\/"},"wordCount":1010,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inhibikase-therapeutics-appoints-scott-wasserman-to-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0OTc5NiM3OTA2ODk5IzIxNTY3NjI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inhibikase-therapeutics-appoints-scott-wasserman-to-board-of-directors\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/inhibikase-therapeutics-appoints-scott-wasserman-to-board-of-directors\/","name":"Inhibikase Therapeutics Appoints Scott Wasserman to Board of Directors - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inhibikase-therapeutics-appoints-scott-wasserman-to-board-of-directors\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inhibikase-therapeutics-appoints-scott-wasserman-to-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0OTc5NiM3OTA2ODk5IzIxNTY3NjI=","datePublished":"2026-10-20T20:22:48+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inhibikase-therapeutics-appoints-scott-wasserman-to-board-of-directors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/inhibikase-therapeutics-appoints-scott-wasserman-to-board-of-directors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inhibikase-therapeutics-appoints-scott-wasserman-to-board-of-directors\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0OTc5NiM3OTA2ODk5IzIxNTY3NjI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0OTc5NiM3OTA2ODk5IzIxNTY3NjI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inhibikase-therapeutics-appoints-scott-wasserman-to-board-of-directors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Inhibikase Therapeutics Appoints Scott Wasserman to Board of Directors"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1011961","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1011961"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1011961\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1011961"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1011961"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1011961"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}